MedPath

Tasimelteon

TASIMELTEON capsules, for oral use

Approved
Approval ID

99cb1928-e57d-4d04-87a1-38108780598a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 24, 2023

Manufacturers
FDA

Amneal Pharmaceuticals NY LLC

DUNS: 123797875

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Tasimelteon

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69238-2548
Application NumberANDA211654
Product Classification
M
Marketing Category
C73584
G
Generic Name
Tasimelteon
Product Specifications
Route of AdministrationORAL
Effective DateJanuary 24, 2023
FDA Product Classification

INGREDIENTS (9)

TASIMELTEONActive
Quantity: 20 mg in 1 1
Code: SHS4PU80D9
Classification: ACTIB
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
GELATINInactive
Code: 2G86QN327L
Classification: IACT
FD&C BLUE NO. 1Inactive
Code: H3R47K3TBD
Classification: IACT
FD&C RED NO. 40Inactive
Code: WZB9127XOA
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tasimelteon - FDA Drug Approval Details